AstraZeneca has entered a deal potentially worth $247 million with AI biologics company Absci to develop a cancer treatment.
Absci Corporation, known for its AI-based antibody discovery, is teaming up with AstraZeneca, a global biopharmaceutical company. They aim to leverage Absci’s technology and AstraZeneca’s oncology expertise to expedite the discovery of a drug that can treat cancer.
Absci’s Integrated drug creation platform utilizes generative AI and scalable wet-lab technologies. It generates exclusive data by assessing millions of protein-protein interactions. This data serves to train Absci’s unique AI models and subsequently validate antibodies designed through AI models.
Puja Sapra, Ph.D., Senior Vice President of Biologics Engineering & Oncology Targeted Delivery at AstraZeneca, expressed enthusiasm about the collaboration, citing it as an exciting chance to employ Absci’s de novo AI antibody creation platform for developing a potential new antibody therapy in oncology.
The agreement comprises initial fees, research funding, milestone payments, and royalties from product sales.